USPTO Examiner BARRON SEAN C - Art Unit 1653

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18651791METHOD FOR ASSESSMENT OF HEPATIC FUNCTION AND PORTAL BLOOD FLOWMay 2024July 2025Allow1500NoNo
18632967CELLS WITH INCREASED IMMUNO-REGULATORY PROPERTIES AND METHODS FOR THEIR USE AND MANUFACTUREApril 2024September 2025Abandon1701NoNo
18628751OLIVE DERIVED CELL CULTURE AND METHODS FOR PREPARING AND USING THE SAMEApril 2024August 2025Allow1610NoNo
18426809COMPOSITIONS, DEVICES AND METHODS FOR THE CONTROL IN VITRO OF CHEMICAL MICROAMBIENT IN CELL CULTURESJanuary 2024February 2026Abandon2520NoNo
18427221BACTERIOPHAGE THERAPYJanuary 2024July 2025Allow1810NoNo
18541671SYSTEMS FOR PRODUCTION OF PRODUCTS TO PROMOTE NITROGEN USE EFFICIENCY IN PLANTSDecember 2023March 2025Allow1511YesNo
18512129LYOPHILIZED POLYMER SCAFFOLD COMPOSITIONS, PROCESSES FOR PREPARATION AND USE IN ANABOLIC WOUND REPAIRNovember 2023April 2025Abandon1710NoNo
18388300DEVICES FOR SIMULATING A FUNCTION OF A TISSUE AND METHODS OF USE AND MANUFACTURING THEREOFNovember 2023April 2025Abandon1710NoNo
18386699METHOD FOR PREPARING BONE GRAFT COMPOSITION AND BONE GRAFT COMPOSITIONNovember 2023September 2025Abandon2320NoNo
18372842MICROTOME SECTIONABLE GEL SUPPORT STRUCTURE AND METHODSSeptember 2023December 2024Allow1410NoNo
18349695METHODS AND DEVICES FOR CELLULAR TRANSPLANTATIONJuly 2023August 2025Abandon2520NoNo
18345891B-CELL CULTIVATION METHODJune 2023February 2025Abandon2010NoNo
18177364PDX1 PANCREATIC ENDODERM CELLS IN CELL DELIVERY DEVICES AND METHODS THEREOFMarch 2023July 2024Allow1610NoNo
18116472CELL SHEET CONSTRUCT FOR NEUROVASCULAR RECONSTRUCTION AND MANUFACTURE THEREOFMarch 2023May 2024Allow1410YesNo
18092429COMPOSITIONS AND METHODS FOR DISRUPTING BIOFILM FORMATION AND MAINTENANCEJanuary 2023October 2024Abandon2111NoNo
18145615PANCREATIC STEM CELLS AND USES THEREOFDecember 2022July 2024Abandon1901NoNo
18069299SPECIFICATION OF FUNCTIONAL CRANIAL PLACODE DERIVATIVES FROM HUMAN PLURIPOTENT STEM CELLSDecember 2022January 2026Allow3621NoNo
18065451ADMINISTRATION OF KYNURENINE DEPLETING ENZYMES FOR TUMOR THERAPYDecember 2022March 2026Allow3920YesNo
17981671MICROBIAL HOST CELLS FOR PRODUCTION OF STEVIOL GLYCOSIDESNovember 2022May 2025Abandon3021YesNo
17959242METHODS TO ENHANCE DELIVERY AND ENGRAFTMENT OF STEM CELLS INCLUDING THE IDENTIFICATION OF SPECIFIC PROSTAGANDIN E2 RECEPTORSOctober 2022August 2024Abandon2311NoNo
17911056MESENCHYMAL STROMAL CELLS AND EXTRACELLULAR VESICLES FOR TREATING VIRAL INFECTIONS, INFLAMMATION, AND TISSUE FIBROSISSeptember 2022January 2026Abandon4001NoNo
17941352METHODS TO DIFFERENTIATE STEM CELLS INTO HORMONE-PRODUCING CELLSSeptember 2022October 2025Allow3712NoNo
17929890CARDIAC FIBROBLAST DERIVED EXTRACELLULAR MATRIXSeptember 2022May 2025Allow3310NoNo
17895697CELLS WITH INCREASED IMMUNO-REGULATORY PROPERTIES AND METHODS FOR THEIR USE AND MANUFACTUREAugust 2022May 2024Abandon2101NoNo
17889776Polymeric Carriers and MethodsAugust 2022February 2024Allow1801YesNo
17890059SYSTEM AND METHOD FOR MAINTAINING ORGAN VIABILITYAugust 2022October 2025Allow3811YesNo
17819220MESENCHYMAL STEM CELLS-HYDROGEL-BIODEGRADABLE OR MESENCHYMAL STEM CELLS-HYDROGEL-NONDEGRADABLE SUPPORT COMPOSITION FOR ALLEVIATING OR IMPROVING EPIDERMOLYSIS BULLOSAAugust 2022May 2025Allow3431NoNo
17798206COATING AGENT FOR INDUCING DIFFERENTIATION OF PLURIPOTENT STEM CELLS INTO BRAIN MICROVASCULAR ENDOTHELIUM-LIKE CELLS AND USE THEREOFAugust 2022December 2025Allow4011YesNo
17759954P450 BM3 MONOOXYGENASE VARIANTS FOR C19-HYDROXYLATION OF STEROIDSAugust 2022November 2025Abandon3911NoNo
17872467OVARIAN-DERIVED HYDROGELS FOR BIOMEDICAL AND BIOTECHNOLOGY APPLICATIONSJuly 2022April 2024Allow2021NoNo
17814044CULTURE AND DIFFERENTIATION OF PLURIPOTENT STEM CELLSJuly 2022December 2025Abandon4121NoNo
17860747DENTAL PRETREATMENT MATERIAL AND DENTAL TISSUE REGENERATION KITJuly 2022May 2024Abandon2210NoNo
17809750MICROORGANISMS AND METHODS FOR THE PRODUCTION OF FATTY ACIDS AND FATTY ACID DERIVED PRODUCTSJune 2022August 2024Allow2511NoNo
17848998ANTI-NET COMPOUNDS FOR TREATING AND PREVENTING FIBROSIS AND FOR FACILITATING WOUND HEALINGJune 2022May 2025Abandon3521NoNo
17838127EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES WITH POTASSIUM CHANNEL AGONISTS AND THERAPEUTIC USES THEREOFJune 2022February 2026Allow4411YesNo
17836922BIOREACTOR PARADIGM FOR THE PRODUCTION OF SECONDARY EXTRA-PARTICLE HYPHAL MATRICESJune 2022June 2025Abandon3721NoNo
17783431CRYOPRESERVED INSECTS AND METHODS FOR PRODUCING SAMEJune 2022October 2025Allow4011NoNo
17827128METHODS OF IMPLANTING ENGINEERED TISSUE CONSTRUCTSMay 2022May 2024Abandon2431NoNo
17732190RECOMBINANT erIL-15 NK CELLSApril 2022April 2025Allow3600NoNo
17437400STAT3 TRANSCRIPTOME FOR DESIGNING MORE POTENT NK CELLSApril 2022October 2025Abandon4901NoNo
17771459SCAFFOLD FOR CELL CULTURE AND MANUFACTURING METHOD THEREOFApril 2022August 2025Allow3911NoNo
17727293IN SITU EXPANSION OF ENGINEERED DEVICES FOR REGENERATIONApril 2022April 2024Abandon2410NoNo
17726498LIQUID-BASED CELL PRESERVATION SOLUTION AND METHOD FOR PREPARING SAMEApril 2022October 2025Abandon4110NoNo
17766745COMPOSITION, FOR PREVENTION OR TREATMENT OF CANCER DISEASE, COMPRISING CYTOTOXIC T CELLS ACTIVATED BY T HELPER CELL-DERIVED EXTRACELLULAR VESICLES AS ACTIVE INGREDIENTApril 2022September 2025Allow4211NoNo
17639618FUSION PROTEINS AND USES THEREOFMarch 2022December 2025Allow4621NoNo
17639170UROTHELIAL CELL INDUCTION AGENT AND METHOD FOR INDUCING UROTHELIAL CELLSFebruary 2022October 2025Abandon4301NoNo
17673455METHANOTHERMOBACTER THERMAUTOTROPHICUS STRAIN AND VARIANTS THEREOFFebruary 2022March 2025Allow3721NoNo
17633414T CELLS HAVING ENHANCED ANTI-TUMOR ACTIVITYFebruary 2022October 2025Allow4411NoNo
17580919METHODS OF TUMOR VACCINATIONJanuary 2022April 2025Allow3911NoNo
17578802METHOD FOR RECOVERING MICROBIAL CELLSJanuary 2022November 2024Abandon3401NoNo
17596889TREATMENT OF AUTISM SPECTRUM DISORDER AND ASSOCIATED NEUROINFLAMMATION USING FIBROBLASTS AND DERIVATIVES THEREOFDecember 2021June 2025Abandon4211NoNo
17550830Manufacturing Process for Polysaccharide BeadsDecember 2021May 2025Allow4111YesNo
17547444CD34+CD41DIM MEGAKARYOCYTES PROGENITORS AND USES THEREOF FOR PRODUCING PROPLATELET-BEARING MKS AND/OR PLATELETSDecember 2021June 2025Abandon4321NoNo
17540619DEVICES FOR SIMULATING A FUNCTION OF A TISSUE AND METHODS OF USE AND MANUFACTURING THEREOFDecember 2021September 2022Allow980NoNo
17536807SOX9-INDUCED OLIGODENDROCYTE PROGENITOR CELLSNovember 2021August 2025Allow4521YesNo
17614225AN ENGINEERED VALVE AND METHOD OF MAKINGNovember 2021July 2025Allow4311NoNo
17613137METHODS OF CULTURING HUMAN PLURIPOTENT CELLSNovember 2021July 2025Allow4411NoNo
17595494SHAPED ORGANOID COMPOSITIONS AND METHODS OF MAKING SAMENovember 2021September 2025Allow4611NoNo
17611669Transplantable cell composition comprising eukaryotic cells in a nanofibrillar cellulose hydrogel, method for preparing thereof and use of nanofibrillar celluloseNovember 2021September 2025Abandon4602NoNo
17608052METHODS OF TREATING DIABETES USING DEVICES FOR CELLULAR TRANSPLANTATIONNovember 2021June 2025Abandon4410NoNo
17594752FIBROBLAST CELL THERAPY FOR TREATMENT OF OSTEOPOROSISOctober 2021October 2025Allow4811YesNo
17606217WISKOTT-ALDRICH SYNDROME GENE HOMING ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USEOctober 2021April 2025Abandon4101NoNo
17504788METHODS FOR MONITORING TREATMENT OF CHRONIC LIVER DISEASEOctober 2021January 2025Allow3931NoNo
17602917METHOD FOR PREPARATION OF CANCER/TESTIS ANTIGEN-SPECIFIC T-CELLSOctober 2021October 2025Abandon4820NoNo
17494322Modified Extracellular Enveloped VirusOctober 2021June 2025Allow4511NoNo
17482674Methods for Regenerating Defective or Absent MyocardiumSeptember 2021December 2025Abandon5011NoNo
17437485MICROGLIAL PROGENITORS FOR REGENERATION OF FUNCTIONAL MICROGLIA IN THE CENTRAL NERVOUS SYSTEM AND THERAPEUTICS USES THEREOFSeptember 2021April 2025Allow4311YesNo
17467834VITRO CULTURE MODEL OF ANISOTROPIC TO ISOTROPIC TRANSITIONSSeptember 2021April 2025Abandon4401NoNo
17434559BACILLUS SUBTILIS NATTO AND METHOD FOR PRODUCING MK-7August 2021August 2025Allow4711NoNo
17432474RECOMBINANT ANTIMICROBIAL MULTIDOMAIN POLYPEPTIDE, METHODS OF PRODUCING AND USES THEREOFAugust 2021January 2026Allow5220NoNo
17404276METHODS AND DEVICES FOR HARVESTING AND PROCESSING CONNECTIVE TISSUE PRECURSOR CELLS FROM AUTOLOGOUS FATAugust 2021February 2024Allow3010YesNo
17394125DELIVERY OF BIOMOLECULES TO IMMUNE CELLSAugust 2021May 2025Allow4540NoNo
17390956PROCESS FOR SIMULTANEOUS PRODUCTION OF CITRIC ACID AND CELLULOLYTIC ENZYMESJuly 2021November 2024Allow3910NoNo
17376341ENGINEERED ARYL SULFATE-DEPENDENT ENZYMESJuly 2021March 2023Allow2021NoNo
17372325HIGH POTENCY STABLE FORMULATIONS OF VAGINAL LACTOBACILLUSJuly 2021January 2025Allow4231YesNo
17353337BACTERIOPHAGE THERAPYJune 2021October 2023Allow2810NoNo
17415456CELL CULTURE SUBSTRATEJune 2021September 2024Allow3910YesNo
17415504CELL CULTURE SUBSTRATEJune 2021May 2025Allow4730NoNo
17343949GENERATION OF GLUCOSE-RESPONSIVE BETA CELLSJune 2021September 2024Abandon3921NoNo
17332718RECOMBINANT FLAVIN-ADENINE DINUCLEOTIDE GLUCOSE DEHYDROGENASE AND USES THEREOFMay 2021March 2025Allow4510NoNo
17303133METHODS OF ENHANCING FIBROBLAST THERAPEUTIC ACTIVITYMay 2021June 2025Allow4940NoNo
17318056CELL CULTUREMay 2021January 2024Allow3211NoNo
17286372PROCESS FOR PRODUCING AMMONIUM (METH-) ACRYLATEApril 2021June 2024Allow3811YesNo
17285948MICROBIAL CELL WITH IMPROVED IN VIVO CONVERSION OF THEBAINE/ORIPAVINEApril 2021August 2025Allow5221NoNo
17227252HUMAN UTERINE CERVICAL STEM CELL POPULATION AND USES THEREOFApril 2021October 2024Allow4221NoNo
17283562FUMONISIN DEGRADING ENZYME FUMDPS AND GENE AND USE THEREOFApril 2021June 2025Allow5020NoNo
17213436IN SITU EXPANSION OF ENGINEERED DEVICES FOR REGENERATIONMarch 2021October 2021Allow711YesNo
17205597COMPOSITIONS AND METHODS FOR TREATING HEART DISEASEMarch 2021April 2025Allow4920NoNo
17186525INFUSED PARTICLESFebruary 2021November 2025Abandon5641NoYes
17181953Compositions for Treatment or Prevention of Infectious Inflammatory Diseases, or Compositions for Immune Enhancement, Comprising, Tryptophanyl-tRNA Synthetase as an Active IngredientFebruary 2021January 2024Abandon3410NoNo
17176569Method of Tissue RepairFebruary 2021January 2024Abandon3510NoNo
17156178REPROGRAMMING OF CELLS TO A NEW FATEJanuary 2021October 2025Abandon5611NoNo
17155059OLIVE DERIVED CELL CULTURE AND METHODS FOR PREPARING AND USING THE SAMEJanuary 2021June 2024Abandon4121NoNo
17148614AGENTS AND METHODS USING THEREOF FOR THE PREVENTION AND TREATMENT OF STEM CELL MUSCLE DISORDERSJanuary 2021January 2025Abandon4821NoYes
17137557CONTROLLED AGGREGATION OF CELLSDecember 2020July 2024Abandon4220NoNo
17129058PROCESS FOR PRODUCING FUEL USING TWO FERMENTATIONSDecember 2020August 2023Allow3201NoNo
17128303METHOD FOR MAKING BIOLOGICAL MATERIAL TRANSPARENT AND USE THEREOFDecember 2020February 2025Abandon5040YesNo
17128654CLEARING REAGENT FOR BIOLOGICAL MATERIAL, AND USE THEREOFDecember 2020February 2025Abandon5040YesNo
17253118EVALUATION METHOD FOR GENOMIC ABNORMALITIES IN CELLSDecember 2020May 2025Abandon5311NoNo
17111147SOFT TISSUE REPAIR AND METHODS FOR PREPARING SAMEDecember 2020October 2023Allow3511NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner BARRON, SEAN C.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
18
Examiner Affirmed
11
(61.1%)
Examiner Reversed
7
(38.9%)
Reversal Percentile
60.4%
Higher than average

What This Means

With a 38.9% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
70
Allowed After Appeal Filing
13
(18.6%)
Not Allowed After Appeal Filing
57
(81.4%)
Filing Benefit Percentile
23.0%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 18.6% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner BARRON, SEAN C - Prosecution Strategy Guide

Executive Summary

Examiner BARRON, SEAN C works in Art Unit 1653 and has examined 612 patent applications in our dataset. With an allowance rate of 52.1%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 39 months.

Allowance Patterns

Examiner BARRON, SEAN C's allowance rate of 52.1% places them in the 14% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by BARRON, SEAN C receive 2.76 office actions before reaching final disposition. This places the examiner in the 81% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by BARRON, SEAN C is 39 months. This places the examiner in the 25% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +32.5% benefit to allowance rate for applications examined by BARRON, SEAN C. This interview benefit is in the 80% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 17.5% of applications are subsequently allowed. This success rate is in the 15% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 18.8% of cases where such amendments are filed. This entry rate is in the 22% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 52.2% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 46% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 62.5% of appeals filed. This is in the 40% percentile among all examiners. Of these withdrawals, 63.3% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.

Petition Practice

When applicants file petitions regarding this examiner's actions, 83.2% are granted (fully or in part). This grant rate is in the 86% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.5% of allowed cases (in the 60% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).

Quayle Actions: This examiner issues Ex Parte Quayle actions in 4.4% of allowed cases (in the 79% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.